Spiromacrocyclic orexin 2 receptor agonists
US-2024425521-A1 · Dec 26, 2024 · US
Spiromacrocyclic orexin 2 receptor agonists
US12590106B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12590106-B2 |
| Application number | US-202519195185-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 30, 2025 |
| Priority date | Jun 1, 2023 |
| Publication date | Mar 31, 2026 |
| Grant date | Mar 31, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel spiro-macrocyclic compounds of general formula (I) which are Orexin 2 receptor agonists.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A compound selected from the group consisting of: N-[(1′S,14R)-6,19-difluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide; N-[(1′S,14R)-19-chloro-6-fluoro-spiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide; N-[(1′S,14R)-6,19-difluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]ethanesulfonamide; N-[(1′S,14R)-6,19-difluoro-11-methyl-spiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide; N-[(1′S,14R)-4,6,17,19-tetrafluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide; and N-[(1′S,14R)-6,17,19-trifluorospiro[8-oxa-12-thia-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide; or a pharmaceutically acceptable salt thereof. 2 . The compound of claim 1 , wherein the compound is N-[(1′S,14R)-6,19-difluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide, or a pharmaceutically acceptable salt thereof. 3 . The compound of claim 1 , wherein the compound is N-[(1′S,14R)-19-chloro-6-fluoro-spiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide, or a pharmaceutically acceptable salt thereof. 4 . The compound of claim 1 , wherein the compound is N-[(1′S,14R)-6,19-difluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]ethanesulfonamide, or a pharmaceutically acceptable salt thereof. 5 . The compound of claim 1 , wherein the compound is N-[(1′S,14R)-6,19-difluoro-11-methyl-spiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide, or a pharmaceutically acceptable salt thereof. 6 . The compound of claim 1 , wherein the compound is N-[(1′S,14R)-4,6,17,19-tetrafluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide, or a pharmaceutically acceptable salt thereof. 7 . The compound of claim 1 , wherein the compound is N-[(1′S,14R)-6,17,19-trifluorospiro[8-oxa-12-thia-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide, or a pharmaceutically acceptable salt thereof. 8 . A pharmaceutical composition comprising the compound of claim 1 , or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. 9 . The pharmaceutical composition of claim 8 together with one or more other therapeutically active compounds. 10 . A compound selected from the group consisting of: 11 . The compound of claim 10 , wherein the compound is: 12 . The compound of claim 10 , wherein the compound is: 13 . The compound of claim 10 , wherein the compound is: 14 . The compound of claim 10 , wherein the compound is 15 . The compound of claim 10 , wherein the compound is: 16 . The compound of claim 10 , wherein the compound is: 17 . A pharmaceutical composition comprising the compound of claim 10 , or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. 18 . The pharmaceutical composition of claim 17 together with one or more other therapeutically active compounds.
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
condensed with heterocyclic ring systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12590106B2 cover?
- The present invention relates to novel spiro-macrocyclic compounds of general formula (I) which are Orexin 2 receptor agonists.
- Who is the assignee on this patent?
- H Lundbeck As
- What technology area does this patent fall under?
- Primary CPC classification C07D498/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).